Sugi Predict

Sugi Predict / Compounds / SCHEMBL1922146

SCHEMBL1922146

SCHEMBL1922146

Cc1cc(C)c(-c2c(C)oc3c(CN4CCCCC4)c(C)nn23)c(C)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.37
▸ ERAP1 Q9NZ08 3/20 0.34
▸ BRD4 O60885 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ KMT2A Q03164 6/20 0.33
▸ KDM4E B2RXH2 4/20 0.33
▸ ALDH1A1 P00352 4/20 0.33
▸ MEN1 O00255 4/20 0.33
▸ POLB P06746 4/20 0.33
▸ L3MBTL1 Q9Y468 3/20 0.33
▸ GLA P06280 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ RECQL P46063 2/20 0.33
▸ BLM P54132 2/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ STAT6 P42226 1/20 0.33
▸ CFB P00751 1/20 0.33
▸ MCL1 Q07820 1/20 0.33
▸ EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924443 0.74 CRHR1 (0.37) CRHR1
SCHEMBL2260399 0.72 MAPK1 (0.36) KDM4EALDH1A1POLB
SCHEMBL1922398 0.70 CRHR1 (0.44) CRHR1
SCHEMBL2259318 0.62 CRHR1 (0.35) KDM4ECRHR1
SCHEMBL3352630 0.61 HRH3 (0.58) HRH3KDM4EALDH1A1POLBGAA
SCHEMBL1922948 0.60 CRHR1 (0.35) CRHR1
SCHEMBL31010210 0.59 BRD4 (0.49) BRD4ALDH1A1
SCHEMBL15872041 0.59 HRH3 (0.54) HRH3KMT2AKDM4EALDH1A1MEN1
SCHEMBL2090689 0.59 HRH3 (0.49) HRH3MAPTKMT2AKDM4EALDH1A1
SCHEMBL12203972 0.59 RAB9A (0.49) HRH3MAPTKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US claimed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP claimed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US claimed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
US-7994203-B2 Organic compounds NOVARTIS AG (CH) 2011-08-09 — — US disclosed
EP-2328902-A1 PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS Novartis AG (CH) 2011-06-08 — — EP disclosed
WO-2010015628-A1 PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS NOVARTIS AG (CH) 2010-02-11 — — WO disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed
US-20100035874-A1 Organic compounds NOVARTIS AG (CH) 2010-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035874-A1 Organic compounds CRH, CRHR1, CRHR2 HRH3 248/4885ERAP1 1271/4885BRD4 1049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback